Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q2 2024 Earnings Report

Gyre Therapeutics logo
$7.19 -0.01 (-0.14%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$7.19 +0.00 (+0.01%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
$25.23 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Monday, August 12, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Gyre Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025

Earnings Documents

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics (GYRE) Projected to Post Quarterly Earnings on Tuesday
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat